The rationale for using a topical retinoid for inflammatory acne

American Journal of Clinical Dermatology

Volumn 4, Issue 2, 2003, Pages 75-80

  Millikan, Larry E ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; ANTIINFECTIVE AGENT; BENZOYL PEROXIDE; BETAMETHASONE VALERATE; CLINDAMYCIN PHOSPHATE; ERYTHROMYCIN; ETRETINATE; GAMMA INTERFERON; INDOMETACIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; ISOTRETINOIN; LIPOXYGENASE; LIPOXYGENASE INHIBITOR; LYMECYCLINE; MATRIX METALLOPROTEINASE; PETROLATUM; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; RETIN A MICRO; RETINOIC ACID; RETINOID; RETINOL; TAZAROTENE; TETRACYCLINE; TOLL LIKE RECEPTOR 2; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ACNE VULGARIS; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; COMEDO; DESQUAMATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG TOLERABILITY; DRUG USE; ENZYME INHIBITION; ERYTHEMA; HORMONAL THERAPY; HUMAN; IMMUNOMODULATION; KERATINIZATION; KERATINOCYTE; MICROENVIRONMENT; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; PROTEIN EXPRESSION; REVIEW; SEBUM SECRETION; SKIN IRRITATION;

ACNE VULGARIS; ADMINISTRATION, TOPICAL; ANTI-BACTERIAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFLAMMATION; KERATOLYTIC AGENTS; MALE; RETINOIDS; TREATMENT OUTCOME;

EID: 0037282322     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200304020-00001     Document Type: Review

References (50)

1. Leyden JJ. Therapy for acne vulgaris. N Engl J Med 1997; 336: 1156-62
2. Cunliffe WJ, Holland DB, Clark SM, et al. Comedogenesis: some new aetiological, clinical and therapeutic strategies. Br J Dermatol 2000; 142: 1084-91
3. Brown SR, Shalita AR. Acne vulgaris. Lancet 1998; 351: 1871-6
4. Leyden JJ. The evolving role of Propionibacterium acnes in acne. Semin Cutan Med Surg 2001; 20: 139-43
5. Guy R, Kealey T. Modeling the infundibulum in acne. Dermatology 1998; 196: 32-7
6. Eady EA, Cove JH. Is acne an infection of blocked pilosebaceous follicles? Implications for antimicrobial treatment. Am J Clin Dermatol 2000; 1: 201-9
7. Webster GF. Inflammation in acne vulgaris. J Am Acad Dermatol 1995; 33: 247-53
8. Zouboulis CC. Is acne vulgaris a genuine inflammatory disease? Dermatology 2001; 203: 277-9
9. Guy R, Green MR, Kealey T. Modeling acne in vitro. J Invest Dermatol 1996; 106: 176-82
10. Kligman AM. An overview of acne. J Invest Dermatol 1974; 62: 268-87
11. Ingham E, Eady EA, Goodwin CE, et al. Pro-inflammatory levels of interleukin-1α-like bioactivity are present in the majority of open comedones in acne vulgaris. J Invest Dermatol 1992; 98: 895-901
12. Norris JFB, Cunliffe WJ. A histological and immunocytochemical study of early acne lesions. Br J Dermatol 1988; 118: 651-9
13. Layton AM, Morris C, Cunliffe WJ, et al. Immunohistochemical investigation of evolving inflammation in lesions of acne vulgaris. Exp Dermatol 1998; 7: 191-7
14. Layton AM. Optimal management of acne to prevent scarring and psychological sequelae. Am J Clin Dermatol 2001; 2: 135-41
15. Gollnick H. Current perspectives on the treatment of acne vulgaris and implications for future directions. J Eur Acad Dermatol Venereol 2001; 15 Suppl. 3: 1-4
16. Lucky AW, Henderson TA, Olson WH, et al. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol 1997; 37: 746-54
17. Orfanos CE, Zouboulis CC, Almond-Roesler B, et al. Current use and future potential role of retinoids in dermatology. Drugs 1997; 53: 358-88
18. Sporn MB, Roberts AB, Roche NS, et al. Mechanism of action of retinoids. J Am Acad Dermatol 1986; 15: 756-64
19. Shroot B, Michel S. Pharmacology and chemistry of adapalene. J Am Acad Dermatol 1997; 36: S96-103
20. Webster GF, McGinley KJ, Leyden JJ. Inhibition of lipase production in Propionibacterium acnes by sub-minimal-inhibitory concentrations of tetracycline and erythromycin. Br J Dermatol 1981; 104: 453-7
21. Webster GF, Leyden JJ, McGinley KJ, et al. Suppression of polymorphonuclear leukocyte chemotactic factor production in Propionibacterium acnes by sub-minimal inhibitory concentrations of tetracycline, ampicillin, minocycline, and erythromycin. Antimicrob Agents Chemother 1982; 21: 770-2
22. Esterly NB, Furey NL, Flanagan LE. The effect of antimicrobial agents on leukocyte chemotaxis. J Invest Dermatol 1978; 70: 51-5
23. Miyachi Y, Yoshioka A, Imamura S, et al. Effect of antibiotics on the generation of reactive oxygen species. J Invest Dermatol 1986; 86: 449-53
24. Hegemann L, Toso SM, Kitay K, et al. Anti-inflammatory actions of benzoyl peroxide: effects on the generation of reactive oxygen species by leucocytes and the activity of protein kinase C and calmodulin. Br J Dermatol 1994; 130: 569-75
25. Wauben-Penris PJJ, Cerneus DP, van den Hoven WE, et al. Immunomodulatory effects of tretinoin in combination with clindamycin. J Eur Acad Dermatol Venereol 1998; 11 Suppl. 1: S2-7
26. Dillehay DL, Walia AS, Lamon EW. Effects of retinoids on macrophage function and IL-1 activity. J Leukoc Biol 1988; 44: 353-60
27. Hensby C, Cavey D, Bouclier M, et al. The in vivo and in vitro anti-inflammatory activity of CD271: a new retinoid-like modulator of cell differentiation. Agents Actions 1990; 29: 56-8
28. Data on file, Galderma LP
29. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 2000; 406: 782-7
30. Czernielewski J, Michel S, Bouclier M, et al. Adapalene biochemistry and the evolution of a new topical retinoid for treatment of acne. J Eur Acad Dermatol Venereol 2001; 15 Suppl. 3: 5-12
31. Duvic M. Pharmacologic profile of tazarotene. Cutis 1998; 61 Suppl. 2: 22-6
32. Cunliffe WJ, Caputo R, Dreno B, et al. Clinical efficacy and safety comparison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and US multicenter trials. J Am Acad Dermatol 1997; 36: S126-34
33. Grosshans E, Marks R, Mascaro JM, et al. Evaluation of clinical efficacy and safety of adapalene 0.1% gel versus tretinoin 0.025% gel in the treatment of acne vulgaris, with particular reference to the onset of action and impact on quality of life. Br J Dermatol 1998; 139 Suppl. 52: 26-33
34. Lucky A, Jorizzo JL, Rodriguez D, et al. Efficacy and tolerance of adapalene cream 0. 1% compared with its cream vehicle for the treatment of acne vulgaris. Cutis 2001; 68: 34-40
35. Ellis CN, Millikan LE, Smith EB, et al. Comparison of adapalene 0.1% solution and tretinoin 0.025% gel in the topical treatment of acne vulgaris. Br J Dermatol 1998; 139 Suppl. 52: 41-7
36. Thiboutot D, Gold MH, Jarratt MT, et al. Randomized controlled trial of the tolerability, safety, and efficacy of adapalene gel 0.1% and tretinoin microsphere gel 0.1% for the treatment of acne vulgaris. Cutis 2001; 68: 10-9
37. Lucky AW, Cullen SI, Funicella T, et al. Double-blind, vehicle-controlled, multicenter comparison of two 0.025% tretinoin creams in patients with acne vulgaris. J Am Acad Dermatol 1998; 38: S24-30
38. Webster GF, Berson D, Stein LF, et al. Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial. Cutis 2001; 67: 4-9
39. Kakita L. Tazarotene versus tretinoin or adapalene in the treatment of acne vulgaris. J Am Acad Dermatol 2000; 43: 551-4
40. Cunliffe WJ, Poncet M, Loesche C, et al. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a meta-analysis of five randomized trials. Br J Dermatol 1998; 139 Suppl. 52: 48-56
41. Wolf JE. An update of recent clinical trials examining adapalene and acne. J Eur Acad Dermatol Venereol 2001; 15 Suppl. 3: 23-9
42. Webster GF, Guenther L, Poulin YP, et al. A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris. Cutis 2002; 69 Suppl. 2S: 4-11
43. Nyirady J, Grossman RM, Nighland M, et al. A comparative trial of two retinoids commonly used in the treatment of acne vulgaris. J Dermatolog Treat 2001; 12: 149-57
44. Leyden JJ. Topical treatment of acne vulgaris: retinoids and cutaneous irritation. J Am Acad Dermatol 1998; 38 (4): S1-4
45. Leyden J, Lowe N, Kakita L, et al. Comparison of treatment of acne vulgaris with alternate-day applications of tazarotene 0.1% gel and once-daily applications of adapalene 0.1% gel: a randomized trial. Cutis 2001; 67 Suppl. 6: 10-6
46. Shalita A. The integral role of topical and oral retinoids in the early treatment of acne. J Eur Acad Dermatol Venereol 2001; 15 Suppl. 3: 43-9
47. Queille-Roussel C, Poncet M, Mesaros S, et al. Comparison of the cumulative irritation potential of adapalene gel and cream with that of erythromycin/tretinoin solution and gel and erythromycin/isotretinoin gel. Clin Ther 2001; 23: 205-12
48. Zouboulis CC, Derumeaux L, Decroix J, et al. A multicentre, single-blind, randomized comparison of a fixed clindamycin phosphate/tretinoin gel formulation (Velac®) applied once daily and a clindamycin lotion formulation (Dalacin T®) applied twice daily in the topical treatment of acne vulgaris. Br J Dermatol 2000; 143: 498-505
49. Czernielewski J, Loesche C, Poncet M. Efficacy and safety comparison of adapalene gel, 0.1% and clindamycin topical lotion 1% vs clindamycin topical lotion 1% alone in the treatment of acne vulgaris [abstract]. 60th Annual Meeting of the American Academy of Dermatology; 2002 Feb 22-27; New Orleans (LA). 33
50. Soto P, Cunliffe W, Meynadier J, et al. Efficacy and safety of of lymecyeline 300mg plus adapalene 0.1% gel versus lymecycline 300mg plus adapalene gel vehicle in subjects with acne vulgaris [abstract]. 60th Annual Meeting of the American Academy of Dermatology; 2002 Feb 22-27; New Orleans (LA), 36